DYRK1A

Across TCGA pan-cancer cohorts, DYRK1A Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DYRK1A data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DYRK1A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DYRK1A expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BLCA, UCEC, and COAD are the cancer types where DYRK1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.051	0.600	<.001	15	view →
UCEC	DFS	Median	All	0.918	0.618	.014	10	view →
COAD	OS	Median	II,III,IV	0.168	0.602	.008	9	view →
LGG	DFS	Median	All	0.142	0.738	<.001	6	view →
LUSC	OS	Median	II,III,IV	0.302	0.633	.038	6	view →
LIHC	OS	Median	II,III,IV	0.152	0.614	.049	3	view →
SKCM	OS	Median	III,IV	0.527	0.431	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DYRK1A–BLCA (OS)

Open the BLCA breakdown →